international
Life-saving breast cancer and endometriosis drug to be discontinued
Key takeaways
- Zoladex 3.6mg is prescribed to patients to slow the growth of breast cancer or reduce the risk of it recurring.
- Astra Zeneca has announced it will pull a critical breast cancer and endometriosis drug from Australian shelves from November.
- Patients have labelled the decision "cruel" and say they have been blindsided.
Why this matters: an international story with cross-border implications worth tracking.
Zoladex 3.6mg is prescribed to patients to slow the growth of breast cancer or reduce the risk of it recurring. (ABC News: Chris Taylor)
Astra Zeneca has announced it will pull a critical breast cancer and endometriosis drug from Australian shelves from November.
Patients have labelled the decision "cruel" and say they have been blindsided.
Article preview — originally published by ABC Australia. Full story at the source.
Read full story on ABC Australia →
More top stories
Also covered by
The Guardian
Doctors hail drug that spares bladder cancer patients ‘life-changing’ surgery
Yahoo Finance
Celcuity Crashes On Breast Cancer Disappointment; What Happened?
Healthline
GLP-1s Like Ozempic May Help Lower Breast Cancer Risk. Here’s How
Healthline
Groundbreaking New Drug Nearly Doubles Pancreatic Cancer Survival
Aggregated and edited by the Scoop newsroom. We surface news from ABC Australia alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop